Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.

Weniger M., Moir J., Damm M., Maggino L., Kordes M., Rosendahl J., ...More

Surgical oncology, vol.35, pp.285-297, 2020 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 35
  • Publication Date: 2020
  • Doi Number: 10.1016/j.suronc.2020.08.031
  • Journal Name: Surgical oncology
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, EMBASE, MEDLINE
  • Page Numbers: pp.285-297
  • Keywords: Neoadjuvant chemotherapy, Survival, Advanced age, SURVIVAL
  • Acibadem Mehmet Ali Aydinlar University Affiliated: Yes


Introduction: The number of people aged 60 and above will rise from 46 million in 2015 to 157 in 2050 million, exceeding 30% of the population in many western countries. Consequently, the demand for oncological therapy for elderly patients will increase within the next decades. Currently, sufficient data on neoadjuvant therapy (NTx) of pancreatic cancer in elderly patients are lacking.